Compare LQDA & UNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | UNF |
|---|---|---|
| Founded | 2004 | 1936 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.8B |
| IPO Year | 2020 | 1994 |
| Metric | LQDA | UNF |
|---|---|---|
| Price | $77.99 | $290.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 3 |
| Target Price | $41.00 | ★ $238.33 |
| AVG Volume (30 Days) | ★ 2.1M | 136.1K |
| Earning Date | 05-08-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | ★ 51.81 | 2.70 |
| EPS | 0.52 | ★ 4.11 |
| Revenue | $158,320,000.00 | ★ $1,696,489,000.00 |
| Revenue This Year | $278.87 | $3.69 |
| Revenue Next Year | $57.13 | $3.53 |
| P/E Ratio | $148.19 | ★ $70.65 |
| Revenue Growth | ★ 1031.18 | 6.63 |
| 52 Week Low | $16.51 | $147.66 |
| 52 Week High | $82.96 | $295.60 |
| Indicator | LQDA | UNF |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 71.84 |
| Support Level | $70.28 | $258.79 |
| Resistance Level | $82.96 | N/A |
| Average True Range (ATR) | 4.58 | 5.85 |
| MACD | -0.89 | 2.31 |
| Stochastic Oscillator | 61.43 | 84.30 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
UniFirst Corp provides uniform and workwear programs, facility management, and safety supplies and services across North America. It designs, manufactures, rents, cleans, and sells uniforms and protective clothing, including flame-resistant and high-visibility garments. It also offers industrial wiping products, floor mats, cleaning supplies, first aid cabinets, and fire protection services such as inspection and maintenance. Serving various industries, the company provides customized uniforms and specialized cleaning for nuclear and cleanroom facilities. It operates through three segments: Uniform & Facility Service Solutions, First Aid & Safety Solutions, and Other, with the majority of revenue from Uniform & Facility Service Solutions.